Literature DB >> 23465965

Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis.

Leah H Rubin1, C Sue Carter, Jeffrey R Bishop, Hossein Pournajafi-Nazarloo, Margret S H Harris, Scot K Hill, James L Reilly, John A Sweeney.   

Abstract

BACKGROUND: In women with chronic schizophrenia, higher levels of peripheral oxytocin have been associated with lower levels of positive but not negative symptoms. Sex-specific associations between endogenous levels of oxytocin (OT) and arginine vasopressin (AVP) with clinical symptoms and cognition in untreated early course patients have not been examined.
METHOD: Clinical ratings and neuropsychological testing were performed in thirty-eight acutely ill, unmedicated first-episode schizophrenia patients (14 women, 24 men). Serum hormone assays were obtained in patients and thirty-eight demographically similar healthy controls.
RESULTS: Patients demonstrated increased AVP levels compared to controls (p = 0.01). Higher AVP levels were associated with greater positive symptoms (r = 0.58, p = 0.03) and worse verbal learning (r = -0.63, p = 0.02) in female, but not male, patients. OT levels did not statistically differ between patients and controls, and were unrelated to clinical symptoms or cognition in patients.
CONCLUSION: Results suggest an association of endogenous AVP with increased positive symptom severity and worse cognition in untreated female, but not male, schizophrenia patients. Findings support the role of neuroendocrine alterations in acute psychosis and the importance of examining sex-specific neuroendocrine alterations early in the course of schizophrenia.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23465965      PMCID: PMC3622845          DOI: 10.1016/j.schres.2013.01.019

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  70 in total

Review 1.  Neuroendocrine perspectives on social attachment and love.

Authors:  C S Carter
Journal:  Psychoneuroendocrinology       Date:  1998-11       Impact factor: 4.905

2.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

Review 3.  Role of oxytocin in the neuroadaptation to drugs of abuse.

Authors:  Z Sarnyai; G L Kovács
Journal:  Psychoneuroendocrinology       Date:  1994       Impact factor: 4.905

Review 4.  Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication.

Authors:  Rainer Landgraf; Inga D Neumann
Journal:  Front Neuroendocrinol       Date:  2004 Sep-Dec       Impact factor: 8.606

Review 5.  Release of vasopressin within the brain contributes to neuroendocrine and behavioral regulation.

Authors:  R Landgraf; C T Wotjak; I D Neumann; M Engelmann
Journal:  Prog Brain Res       Date:  1998       Impact factor: 2.453

6.  Vasopressin cells in the bed nucleus of the stria terminalis of the rat: sex differences and the influence of androgens.

Authors:  F W van Leeuwen; A R Caffe; G J De Vries
Journal:  Brain Res       Date:  1985-01-28       Impact factor: 3.252

7.  The arginine vasopressin and corticotrophin-releasing hormone gene transcription responses to varied frequencies of repeated stress in rats.

Authors:  X M Ma; S L Lightman
Journal:  J Physiol       Date:  1998-07-15       Impact factor: 5.182

8.  Cerebrospinal fluid neurophysins in affective illness and in schizophrenia.

Authors:  P Linkowski; V Geenen; M Kerkhofs; J Mendlewicz; J J Legros
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1984

9.  Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating.

Authors:  D Feifel; T Reza
Journal:  Psychopharmacology (Berl)       Date:  1999-01       Impact factor: 4.530

10.  Vasopressin--oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls.

Authors:  H Beckmann; R E Lang; W F Gattaz
Journal:  Psychoneuroendocrinology       Date:  1985       Impact factor: 4.905

View more
  26 in total

1.  Peripheral oxytocin and vasopressin modulates regional brain activity differently in men and women with schizophrenia.

Authors:  Leah H Rubin; Siyi Li; Li Yao; Sarah K Keedy; James L Reilly; Scot K Hill; Jeffrey R Bishop; C Sue Carter; Hossein Pournajafi-Nazarloo; Lauren L Drogos; Elliot Gershon; Godfrey D Pearlson; Carol A Tamminga; Brett A Clementz; Matcheri S Keshavan; Su Lui; John A Sweeney
Journal:  Schizophr Res       Date:  2018-07-06       Impact factor: 4.939

2.  Plasma oxytocin levels predict olfactory identification and negative symptoms in individuals with schizophrenia.

Authors:  Gregory P Strauss; William R Keller; James I Koenig; James M Gold; Kathryn L Ossenfort; Robert W Buchanan
Journal:  Schizophr Res       Date:  2015-01-09       Impact factor: 4.939

3.  Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders.

Authors:  Leah H Rubin; C Sue Carter; Jeffrey R Bishop; Hossein Pournajafi-Nazarloo; Lauren L Drogos; S Kristian Hill; Anthony C Ruocco; Sarah K Keedy; James L Reilly; Matcheri S Keshavan; Godfrey D Pearlson; Carol A Tamminga; Elliot S Gershon; John A Sweeney
Journal:  Schizophr Bull       Date:  2014-03-11       Impact factor: 9.306

4.  Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia.

Authors:  Mary R Lee; Heidi J Wehring; Robert P McMahon; Fang Liu; Jared Linthicum; Joseph G Verbalis; Robert W Buchanan; Gregory P Strauss; Leah H Rubin; Deanna L Kelly
Journal:  Schizophr Res       Date:  2016-02-12       Impact factor: 4.939

Review 5.  Potential of Oxytocin in the Treatment of Schizophrenia.

Authors:  Paul D Shilling; David Feifel
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

6.  Endogenous oxytocin levels are associated with facial emotion recognition accuracy but not gaze behavior in individuals with schizophrenia.

Authors:  Michael J Spilka; William R Keller; Robert W Buchanan; James M Gold; James I Koenig; Gregory P Strauss
Journal:  Acta Psychiatr Scand       Date:  2022-03-16       Impact factor: 6.392

7.  Endogenous oxytocin response to film scenes of attachment and loss is pronounced in schizophrenia.

Authors:  Lucas G Speck; Johanna Schöner; Felix Bermpohl; Andreas Heinz; Jürgen Gallinat; Tomislav Majic; Christiane Montag
Journal:  Soc Cogn Affect Neurosci       Date:  2019-01-04       Impact factor: 3.436

8.  Sex and diagnosis specific associations between DNA methylation of the oxytocin receptor gene with emotion processing and temporal-limbic and prefrontal brain volumes in psychotic disorders.

Authors:  Leah H Rubin; Jessica J Connelly; James L Reilly; C Sue Carter; Lauren L Drogos; Hossein Pournajafi-Nazarloo; Anthony C Ruocco; Sarah K Keedy; Ian Matthew; Neeraj Tandon; Godfrey D Pearlson; Brett A Clementz; Carol A Tamminga; Elliot S Gershon; Matcheri S Keshavan; Jeffrey R Bishop; John A Sweeney
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2015-11-09

9.  Correspondence of DNA Methylation Between Blood and Brain Tissue and Its Application to Schizophrenia Research.

Authors:  Esther Walton; Johanna Hass; Jingyu Liu; Joshua L Roffman; Fabio Bernardoni; Veit Roessner; Matthias Kirsch; Gabriele Schackert; Vince Calhoun; Stefan Ehrlich
Journal:  Schizophr Bull       Date:  2015-06-08       Impact factor: 9.306

Review 10.  The promise of biological markers for treatment response in first-episode psychosis: a systematic review.

Authors:  Guillaume Fond; Marc-Antoine d'Albis; Stéphane Jamain; Ryad Tamouza; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Markus Leweke; Shôn Lewis; Phillip McGuire; Andreas Meyer-Lindenberg; Iris E Sommer; Inge Winter-van Rossum; Shitij Kapur; René S Kahn; Dan Rujescu; Marion Leboyer
Journal:  Schizophr Bull       Date:  2015-03-10       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.